Evidence map›Paper›PMID 10463046›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne1999

Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.

C Bourgault, E Elstein, J Le Lorier, S Suissa

Abstract read
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
12.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique · 2008
    Article
  3. Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2002
    Article
  4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2002
    Article
  5. Review
  6. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2001
    Article
  7. Pharmaceutical policies in Canada: another example of federal-provincial discord.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2000
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

C BourgaultDepartment of Epidemiology and Biostatistics, McGill University, Montreal, Que.
E Elstein
J Le Lorier
S Suissa
McGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReference-based pricing is a cost-containment policy applied to prescription drugs that are in the same class and deemed to be therapeutically equivalent. Recent reference-based pricing measures have targeted several drug classes, including angiotensin-converting-enzyme (ACE) inhibitors. The objective of this study was to assess whether patients treated for hypertension with various ACE inhibitors differed in their utilization of health care services and hence, whether the various ACE inhibitors should be considered therapeutically equivalent.

methodsA retrospective cohort was formed from 4709 Saskatchewan residents aged 40-79 years who initiated treatment for hypertension with 1 of the 3 most frequently prescribed ACE inhibitors (captopril, enalapril or lisinopril) between Jan. 1, 1991, and Dec. 31, 1993. Information obtained from universal insurance databases included prescription drug use, the number of visits to a general practitioner (GP) or specialist and the number of hospital admissions during the year before treatment was initiated and during a follow-up period of up to 4 years. Rates were statistically adjusted for potential confounding variables and compared across treatment groups.

resultsOf the 4709 patients, 529 were prescribed captopril initially, 2939 enalapril and 1241 lisinopril. After treatment was initiated patients prescribed captopril were dispensed more medications on average, with an overall rate of 18.6 prescriptions per patient per year (v. 16.4 and 14.7 for enalapril and lisinopril users respectively); they were admitted to hospital more often, and they made more visits to GPs and specialists. The adjusted rate ratio of the number of visits to a GP for patients receiving enalapril, relative to captopril, was 0.84 (95% confidence interval [CI] 0.80-0.88), and for those receiving lisinopril it was 0.79 (95% CI 0.74-0.83). The adjusted rate ratios for the number of visits to a specialist were similar but lower, and for the number of hospital admissions they were 0.82 for patients prescribed enalapril initially (95% CI 0.73-0.93) and 0.65 (95% CI 0.56-0.75) for those prescribed lisinopril.

interpretationPatients with hypertension who are initially prescribed captopril used health care services more than those initially prescribed enalapril or lisinopril. This suggests that ACE inhibitors may not be therapeutically equivalent.

Indexed as

Economics, PharmaceuticalAdultAgedAngiotensin-Converting Enzyme InhibitorsCohort StudiesCost ControlDrug PrescriptionsFemaleHealth ServicesHumansHypertensionMaleMiddle AgedRetrospective StudiesTherapeutic EquivalencyAngiotensin-Converting Enzyme Inhibitors

Identifiers

PMID10463046
PMCPMC1230501
OpenAlexW2135195489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.